124953-60-2

Basic information

• Product Name: 5-Isoxazolecarbonyl chloride, 3-phenyl- (9CI)
• Synonyms: 5-Isoxazolecarbonyl chloride, 3-phenyl- (9CI);3-Phenylisoxazole-5-carbonyl chloride;5-(Chlorocarbonyl)-3-phenylisoxazole
• CAS NO: 124953-60-2
• Molecular Formula: C₁₀H₆ClNO₂
• Molecular Weight: 207.61314
• Product Categories: ACIDHALIDE
• Mol File: 124953-60-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 90.5-91.5°C
• Boiling Point: 370.2°Cat760mmHg
• Flash Point: 177.7°C
• Appearance: /
• Density: 1.321g/cm³
• Vapor Pressure: 1.12E-05mmHg at 25°C
• Refractive Index: 1.568
• CAS DataBase Reference: 5-Isoxazolecarbonyl chloride, 3-phenyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoxazolecarbonyl chloride, 3-phenyl- (9CI)(124953-60-2)
• EPA Substance Registry System: 5-Isoxazolecarbonyl chloride, 3-phenyl- (9CI)(124953-60-2)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 124953-60-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H6ClNO2/c11-10(13)9-6-8(12-14-9)7-4-2-1-3-5-7/h1-6H

Upstream product

• 14442-12-7 3-phenylisoxazole-5-carboxylic acid 
• 932-90-1 Benzaldoxime 
• 698-16-8 benzohydroximoyl chloride 
• 90924-12-2 3-phenyl-5-hydroxymethylisoxazole 
• 100-52-7 benzaldehyde 

Downstream Products

• 124953-37-3 (3-Phenyl-isoxazol-5-yl)-piperazin-1-yl-methanone 
• 124953-46-4 4-(3-Phenyl-isoxazole-5-carbonyl)-piperazine-1-carbothioic acid (2-cyano-4,5-dimethoxy-phenyl)-amide 

Relevant articles and documents

Design, synthesis, and optimization of a series of 2-azaspiro[3.3]heptane derivatives as orally bioavailable fetal hemoglobin inducers

Pharmacological reactivation of the γ-globin gene for the production of fetal hemoglobin (HbF) is a promising approach for the management of β-thalassemia and sickle cell disease (SCD). We conducted a phenotypic screen in human erythroid progenitor cells

METHODS OF TREATING PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.

NOVEL THERAPEUTIC COMPOUNDS

Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.